Diabetic Med:为Ⅰ型糖尿病儿童,青少年和家庭开发可接受和可行的自我管理小组

2017-06-28 MedSci MedSci原创

近日,国际杂志 《Diabetic medicine》上在线发表一项关于为Ⅰ型糖尿病儿童,青少年和家庭开发可接受和可行的自我管理小组的研究,这项研究开发了可接受和可行的自我管理干预措施,解决了Ⅰ型糖尿病儿童和青少年及其父母的的自我确认的需求。

近日,国际杂志 《Diabetic medicine》上在线发表一项关于为Ⅰ型糖尿病儿童,青少年和家庭开发可接受和可行的自我管理小组的研究,这项研究开发了可接受和可行的自我管理干预措施,解决了Ⅰ型糖尿病儿童和青少年及其父母的的自我确认的需求。

第一阶段审查了以前的干预措施,并对临床小组,年轻人和家庭进行了采访。第二阶段有三个与年龄相匹配的重点小组,包括11816岁的儿童家庭。反馈用于修改研讨会内容。第3阶段评估了交付的可行性,以及在基线和干预后1-3个月测量的对代谢控制,生活质量和低血糖恐惧的影响。

八十九个家庭被邀请参加。二十二个(25%)参加了七个试点小组(年龄中位数10岁,女生36%)。干预措施包括为青少年和家长提供一个适合发展的研讨会:(1)血糖控制,(2)长期高HbA 1c的潜在影响,(3)高血糖和低血糖影响,(4)自我管理技巧和(5)自信地向人们介绍糖尿病。参与者对讲习班热情洋溢,并向其他人推荐。年轻人喜欢分享思想,与糖尿病患者会面,而父母则喜欢听孩子们谈糖尿病知识。

研究认为,Ⅰ型糖尿病的家庭参与了自我管理组织的干预。虽然存在可接受性和可行性,但是试点研究结果并不支持随机对照试验的开发以评估改善HbA 1c的有效性。

原始出处:

R. A. Cai, R. I. G. Holt, L. Casdagli, et al. Development of an acceptable and feasible self-management group for children, young people and families living with Type 1 diabetes.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760066, encodeId=df461e6006682, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 28 22:43:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970482, encodeId=594119e0482f1, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Oct 18 17:43:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637869, encodeId=5da7163e869b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 30 10:43:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435075, encodeId=33ed14350e532, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jun 30 10:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607737, encodeId=d852160e737fa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 30 10:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760066, encodeId=df461e6006682, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 28 22:43:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970482, encodeId=594119e0482f1, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Oct 18 17:43:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637869, encodeId=5da7163e869b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 30 10:43:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435075, encodeId=33ed14350e532, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jun 30 10:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607737, encodeId=d852160e737fa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 30 10:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760066, encodeId=df461e6006682, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 28 22:43:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970482, encodeId=594119e0482f1, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Oct 18 17:43:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637869, encodeId=5da7163e869b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 30 10:43:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435075, encodeId=33ed14350e532, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jun 30 10:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607737, encodeId=d852160e737fa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 30 10:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760066, encodeId=df461e6006682, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 28 22:43:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970482, encodeId=594119e0482f1, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Oct 18 17:43:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637869, encodeId=5da7163e869b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 30 10:43:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435075, encodeId=33ed14350e532, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jun 30 10:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607737, encodeId=d852160e737fa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 30 10:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1760066, encodeId=df461e6006682, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 28 22:43:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970482, encodeId=594119e0482f1, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Oct 18 17:43:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637869, encodeId=5da7163e869b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 30 10:43:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435075, encodeId=33ed14350e532, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jun 30 10:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607737, encodeId=d852160e737fa, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 30 10:43:00 CST 2017, time=2017-06-30, status=1, ipAttribution=)]

相关资讯

Diabetes Obes Metab:β-受体阻断剂能否降低2型糖尿病合并冠心病患者的死亡率

β-受体阻断剂是心血管病治疗的主要药物之一。2017年6月,发表在《Diabetes Obes Metab》上的一项研究评估β-受体阻断剂是否会影响糖尿病合并冠心病(CHD)患者的死亡率和主要心血管事件发生率。结果显示,β-受体阻断剂使用能有效降低MI/HFrEF患者的全因死亡率,但对无MI/HFrEF的患者没有作用。

Diabetes Obes Metab:妊娠期糖尿病:二甲双胍可替代胰岛素?

妊娠期使用二甲双胍仍存在争议。2017年6月,发表在《Diabetes Obes Metab》的一篇综述在回顾相关文献后认为,二甲双胍作为妊娠期糖尿病(GDM)胰岛素治疗的替代选择。

Diabetic Med:社区级别不平等对儿科糖尿病护理的影响

近日,国际杂志 《Diabetic medicine》上在线发表一项关于社区级别不平等对儿科糖尿病护理的影响的研究。使用社区权益指数(NEI)评估儿科1型糖尿病在社区级别不平等与血糖控制之间的关系。

Diabetic Med:行政和临床病例定义对妊娠糖尿病的验证的有效性如何?

近日,国际杂志 《Diabetic medicine》上在线发表一项关于对妊娠糖尿病的行政和临床病例定义的验证与实验室结果相比较的研究。目的是以实验室数据作为“金标准”,验证行政数据库(门诊和住院病人)和临床围产期数据库(艾伯塔省围产期健康计划)中国际疾病分类第10版(ICD-10)代码对妊娠期糖尿病的诊断的有效性。

Diabetic Med:79-97岁男性糖尿病的状况如何?

近日,国际杂志 《Diabetic medicine》上在线发表一项关于西澳大利亚79-97岁糖尿病男性的健康状况,目的在于调查与老年男性糖尿病相关的行为,生理和生化特征。 研究人员对西澳大利亚珀斯的79-97岁的社区居民进行横断面分析。评估了生活方式行为,自我评估健康,生理功能,空腹血糖和HbA 1c水平。

Diabetic Med:糖化血红蛋白(HbA 1c)和空腹血浆葡萄糖在海平面和高海拔环境中的差异及其意义

近日,国际杂志 《Diabetic medicine》上在线发表一项关于糖化血红蛋白(HbA 1c)和空腹血浆葡萄糖在海平面和高海拔环境中关系的研究。 高原居民报告血红蛋白水平升高,葡萄糖代谢差异有可能影响HbA 1c的诊断性能。本研究探讨了生活在海平面和> 3000米高海拔的人群中HbA 1c与空腹血浆葡萄糖(FPG)之间的关系。